Stella Diagnostics, Inc. (OTC: SLDX) is a molecular diagnostics-based organization focused on improving patient management strategies for over 67 million people living with severe esophageal disease. StellaDX’s clinical assay will offer physicians insight into the molecular properties of their patients’ tissue to determine if the disease is stable, progressing or turning cancerous. Using targeted mass spectrometry proteomics, we believe that informing physicians of the expression patterns playing a role in the pathogenesis of GERD, Barrett’s esophagus and esophageal cancer early in the treatment plan may extend or save lives. For more information, please visit www.StellaDX.com.
Stella Diagnostics has multiple collaborative research agreements with leading institutions around the U.S., including Mayo Clinic. For more information on this collaboration and Stella Diagnostics’ technology, SCV points listeners to the Company’s investor page at https://www.stelladx.com/investors/investor-deck-and-news.
Esophageal cancer is the fastest-rising, deadliest cancer in the United States. Early detection of the disease significantly increases a patient’s survival rate and quality of life, though routine screening generally catches cancers in the advanced stages.
Speaking with SmallCapVoice’s Stuart Smith, Dr. Abdo explains how Stella Diagnostics’ assays quantify the presence of good or harmful protein within biopsy tissue and raise the bar for the current standard of care for Barrett’s screening.
“When we analyze precancerous tissue, we can inform physicians if that tissue is actually possessive of a carcinogenic molecular properties,” he says. “We’ll take biopsies and look at the growth aspects of the cell structure, cell organization, cell differentiation. There’s no molecular information that’s being assessed with the current standard of care for people that have precancerous diseases like Barrett’s esophagus.”
To hear the full interview with SCV, visit: https://www.smallcapvoice.com/interview-stella-diagnostics-sldx/.
